Table 1

IRs and HRs of PE and DVT for tofacitinib 5 and 10 mg twice daily versus TNFi (95% CI) from the ad hoc safety analysis of ongoing Study A3921133 (data cut-off: February 2019; database not locked; data not yet source-verified or subjected to standard quality-check procedures that would occur at the time of database lock and may therefore be subject to change)

Safety endpointTofacitinib
5 mg twice daily
Tofacitinib
10 mg twice daily
TNFi
PEIR (95% CI)0.27 (0.12 to 0.52)0.54 (0.32 to 0.87)0.09 (0.02 to 0.26)
HR versus TNFi (95% CI)2.99 (0.81 to 11.06)5.96 (1.75 to 20.33)
DVTIR (95% CI)0.30 (0.14 to 0.55)0.38 (0.20 to 0.67)0.18 (0.07 to 0.39)
HR versus TNFi (95% CI)1.66 (0.60 to 4.57)2.13 (0.80 to 5.69)
Subgroup analysis in patients with VTE risk factors
PEHR versus TNFi (95% CI)3.92 (0.83 to 18.48)9.14 (2.11 to 39.56)
  • DVT, deep vein thrombosis; IR, incidence rate (unique patients with events per 100 patient-years); PE, pulmonary embolism; TNFi, tumour necrosis factor inhibitor; VTE, venous thromboembolism.